GlassScriptPhysician profile
Tasneem Peeraully
NPI 1346516515
$826.99
in general payments reported to CMS, 2019-2025
16 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $82.90 · 2023: $28.80 · 2024: $141 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $530.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $155.07 | 2023-2025 | |
| Mdd US Operations, LLC | $152.34 | 2019-2025 | Apokyn |
| Boston Scientific Corporation | $119.56 | 2019-2024 | |
| Insightec,INC | $82.94 | 2025 | Exablate |
| Medtronic, INC. | $70.60 | 2024 | Percept PC Brainsense |
| Abbott Laboratories | $65.17 | 2025 | Infinity |
| Teva Pharmaceuticals USA, INC. | $43.78 | 2019 | |
| Merz North America, INC. | $25.53 | 2019 | |
| Merz Pharmaceuticals, LLC | $17.43 | 2025 | Xeomin |
| Allergan, INC. | $14.97 | 2020 | |
| Supernus Pharmaceuticals, INC. | $14.66 | 2019 | |
| Ge Healthcare | $14.35 | 2020 | |
| Acorda Therapeutics, INC | $13.81 | 2019 | |
| Ucb, INC. | $13.19 | 2019 | |
| Zyla Life Sciences, INC. | $12.61 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tasneem Peeraully listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.